Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DBT010
MIFTS: 53

Diabetic Neuropathy

Categories: Neuronal diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Diabetic Neuropathy

About this section

MalaCards integrated aliases for Diabetic Neuropathy:

Name: Diabetic Neuropathy 11 52 75 14 36 16
Diabetic Neuropathies 53 71

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:9743
ICD9CM 34 250.6
MeSH 43 D003929
NCIt 49 C26748
SNOMED-CT 68 193182005
UMLS 71 C0011882
Sources

Summaries for Diabetic Neuropathy

About this section

NINDS: 52 Diabetic neuropathy is a peripheral nerve disorder caused by diabetes or poor blood sugar control. The most common types of diabetic neuropathy result in problems with sensation in the feet. It can develop slowly after many years of diabetes or may occur early in the disease. The symptoms are numbness, pain, or tingling in the feet or lower legs. The pain can be intense and require treatment to relieve the discomfort. The loss of sensation in the feet may also increase the possibility that foot injuries will go unnoticed and develop into ulcers or lesions that become infected. In some cases, diabetic neuropathy can be associated with difficulty walking and some weakness in the foot muscles. There are other types of diabetic-related neuropathies that affect specific parts of the body. For example, diabetic amyotrophy causes pain, weakness and wasting of the thigh muscles, or cranial nerve infarcts that may result in double vision, a drooping eyelid, or dizziness. Diabetes can also affect the autonomic nerves that control blood pressure, the digestive tract, bladder function, and sexual organs. Problems with the autonomic nerves may cause lightheadedness, indigestion, diarrhea or constipation, difficulty with bladder control, and impotence.

MalaCards based summary: Diabetic Neuropathy, also known as diabetic neuropathies, is related to microvascular complications of diabetes 3 and diabetic polyneuropathy, and has symptoms including sciatica and neuralgia. An important gene associated with Diabetic Neuropathy is AKR1B1 (Aldo-Keto Reductase Family 1 Member B), and among its related pathways/superpathways are MIF Mediated Glucocorticoid Regulation and CREB Pathway. The drugs Histamine and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, bone marrow and dorsal root ganglion, and related phenotypes are homeostasis/metabolism and nervous system

Wikipedia: 75 Diabetic neuropathy is various types of nerve damage associated with diabetes mellitus. Symptoms depend... more...
Sources

Related Diseases for Diabetic Neuropathy

About this section

Diseases related to Diabetic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 446)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 3 32.2 INS AKR1B1 AGER ACE
2 diabetic polyneuropathy 32.1 VEGFA TRPV1 NTF3 NGF INS CNTF
3 diabetic angiopathy 32.1 VEGFA SOD2 INS AGER
4 neuropathy 32.1 VEGFA TRPV4 SORD SOD2 PMP22 NTRK1
5 microvascular complications of diabetes 5 32.1 VEGFA SORD SOD2 INS AKR1B1 AGER
6 type 2 diabetes mellitus 31.7 VEGFA SOD3 SOD2 NGF INS CNTF
7 hyperglycemia 31.7 SORD SOD2 INS AKR1B1 AGER
8 polyneuropathy 31.7 PMP22 NGF MPZ GDNF CNTF AKR1B1
9 autonomic neuropathy 31.4 NTRK1 NTF3 NGFR NGF INS EPO
10 peripheral vascular disease 31.2 VEGFA INS EPO ACE
11 diabetic autonomic neuropathy 31.1 NTF3 NGF INS AKR1B1 ACE
12 mononeuropathy 31.1 TRPV1 PMP22 NGF MPZ ACE
13 impotence 31.0 VEGFA NGF ACE
14 neurogenic arthropathy 30.9 NTRK1 NGF INS
15 hypoglycemia 30.9 VEGFA INS AKR1B1 ACE
16 diabetes mellitus 30.9 VEGFA SORD SOD3 SOD2 NGF INS
17 sensory peripheral neuropathy 30.8 TRPV1 PMP22 NTRK1 NTF3 NGF MPZ
18 wallerian degeneration 30.8 VEGFA MPZ CNTF
19 pain agnosia 30.8 TRPV1 TRPM8 NGF INS
20 carpal tunnel syndrome 30.7 VEGFA PMP22 MPZ INS ACE
21 paine syndrome 30.6 TRPV4 TRPV1 TRPM8 NGF
22 neuritis 30.6 VEGFA PMP22 MPZ GDNF CNTF
23 sleep apnea 30.6 VEGFA INS EPO ACE
24 anhidrosis 30.6 NTRK1 NGFR NGF
25 apnea, obstructive sleep 30.6 VEGFA INS ACE
26 peripheral nervous system disease 30.6 VEGFA TRPV4 TRPV1 TRPM8 SORD PMP22
27 complex regional pain syndrome 30.5 TRPV1 TRPM8 NGF
28 ischemia 30.5 VEGFA SOD2 EPO ACE
29 uremia 30.5 INS EPO ACE
30 anxiety 30.5 TRPV1 NGF INS GDNF ACE
31 nerve compression syndrome 30.5 TRPV1 PMP22 NGF MPZ INS
32 peripheral artery disease 30.4 VEGFA INS ACE
33 roussy-levy hereditary areflexic dystasia 30.4 PMP22 MPZ
34 neurogenic bladder 30.4 TRPV1 NGF INS ACE
35 hereditary sensory neuropathy 30.3 NTRK1 NGF MPZ
36 ulnar neuropathy 30.3 PMP22 MPZ
37 respiratory failure 30.3 VEGFA INS AGER ACE
38 erythromelalgia 30.3 TRPV4 TRPV1 TRPM8 NGF
39 silent myocardial infarction 30.3 INS ACE
40 uremic neuropathy 30.3 TRPV1 EPO
41 keratopathy 30.3 VEGFA NGF AKR1B1
42 cataract 30.2 VEGFA SORD SOD3 SOD2 INS AKR1B1
43 demyelinating disease 30.2 NTF3 NGF MPZ CNTF
44 decubitus ulcer 30.2 VEGFA NGF INS
45 ischemic neuropathy 30.2 VEGFA CNTF
46 kidney disease 30.2 VEGFA INS EPO AKR1B1 AGER ACE
47 end stage renal disease 30.2 VEGFA SOD2 EPO ACE
48 amyotrophic lateral sclerosis 1 30.1 VEGFA SOD2 NTRK1 NTF3 NGFR NGF
49 hereditary neuropathies 30.1 PMP22 MPZ
50 plexopathy 30.1 PMP22 MPZ

Graphical network of the top 20 diseases related to Diabetic Neuropathy:



Diseases related to Diabetic Neuropathy
Sources

Symptoms & Phenotypes for Diabetic Neuropathy

About this section

UMLS symptoms related to Diabetic Neuropathy:


sciatica; neuralgia

GenomeRNAi Phenotypes related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 ACE AGER AKR1B1 CNTF EPO GDNF
2 no effect GR00402-S-2 10.18 ACE AGER EPO GDNF INS NGF

MGI Mouse Phenotypes related to Diabetic Neuropathy:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 ACE AGER AKR1B1 CNTF EPO INS
2 nervous system MP:0003631 10.36 CNTF GDNF INS MPZ NGF NGFR
3 muscle MP:0005369 10.32 AGER CNTF EPO GDNF INS NGF
4 growth/size/body region MP:0005378 10.25 ACE AGER AKR1B1 GDNF INS NGF
5 behavior/neurological MP:0005386 10.25 ACE AGER AKR1B1 CNTF GDNF INS
6 normal MP:0002873 10.19 AGER INS NGF NGFR NTF3 NTRK1
7 renal/urinary system MP:0005367 10.19 ACE AGER AKR1B1 GDNF INS NGFR
8 cellular MP:0005384 10.18 ACE AGER CNTF EPO GDNF INS
9 cardiovascular system MP:0005385 10.18 ACE AGER EPO GDNF INS NGF
10 no phenotypic analysis MP:0003012 10.07 CNTF INS NGF NTRK1 SOD3 TRPV1
11 immune system MP:0005387 10.07 ACE AGER CNTF EPO GDNF INS
12 vision/eye MP:0005391 9.9 AKR1B1 INS NGF NGFR NTF3 NTRK1
13 mortality/aging MP:0010768 9.8 ACE AKR1B1 EPO GDNF INS MPZ
14 integument MP:0010771 9.36 AGER INS MPZ NGF NGFR NTRK1
Sources

Drugs & Therapeutics for Diabetic Neuropathy

About this section

Drugs for Diabetic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 267)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6 774
2
Acetaminophen Approved Phase 4 103-90-2 1983
3
Amitriptyline Approved Phase 4 50-48-6 2160
4
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
5
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
6
Cetirizine Approved Phase 4 83881-51-0 2678
7
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
8
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
9
Nabilone Approved, Investigational Phase 4 51022-71-0 39860 5284592
10
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
11
Bromocriptine Approved, Investigational, Withdrawn Phase 4 25614-03-3 31101
12
Quinapril Approved, Investigational Phase 4 82586-55-8, 85441-61-8 54892
13
Dapagliflozin Approved Phase 4 461432-26-8 9887712
14
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
15
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
16
Donepezil Approved Phase 4 120014-06-4 3152
17
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
18
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
19
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
20
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
21
Pyridoxal phosphate Approved, Investigational, Nutraceutical Phase 4 54-47-7 1051
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
23
Lipoic acid Approved, Investigational, Nutraceutical Phase 4 1200-22-2 864 6112
24
Cysteine Approved, Nutraceutical Phase 4 52-90-4 594 5862
25 Antihypertensive Agents Phase 4
26 Anti-Allergic Agents Phase 4
27 Antiemetics Phase 4
28
Histamine phosphate Phase 4 51-74-1 134614
29 Histamine H1 Antagonists Phase 4
30 Histamine Antagonists Phase 4
31 Gastrointestinal Agents Phase 4
32 Antiparkinson Agents Phase 4
33 Antipyretics Phase 4
34 Linoleate Phase 4
35 Calciferol Phase 4
36 Antimetabolites Phase 4
37 Hypolipidemic Agents Phase 4
38 Anticholesteremic Agents Phase 4
39 Lipid Regulating Agents Phase 4
40 Cholestyramine Resin Phase 4
41 Insulin, Globin Zinc Phase 4
42
Insulin Phase 4
43 Histamine H1 Antagonists, Non-Sedating Phase 4
44 Phosphodiesterase Inhibitors Phase 4
45 Phosphodiesterase 5 Inhibitors Phase 4
46 Citrate Phase 4
47 Hypoglycemic Agents Phase 4
48 Hormone Antagonists Phase 4
49 HIV Protease Inhibitors Phase 4
50
protease inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 493)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
2 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
3 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
4 Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
5 A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy Completed NCT03914404 Phase 4 γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
6 The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Patients With Diabetic Peripheral Neuropathic Pain: a Randomized, Placebo-controlled Study of South Asian Male Patients Completed NCT04238208 Phase 4 Lidocaine 5% patch;Capsaicin 8% Patch, Per 10 Square Centimeters
7 PRELIMINARY EVALUATION OF RETINAL EFFECTS OF PHARMACOLOLOGICAL LOWERING OF SERUM LEVES OF ADVANCED GLYCATION END-PRODUCTS (AGEs) IN TYPE 2 DIABETIC PATIENTS Completed NCT02249897 Phase 4 CHOLESTYRAMINE
8 An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
9 Gabapentin Kinetic Disposition and Renal Excretion: Role of Transporters for Organic Cations and the Effect of Glycemic Control in Patients With Neuropathic Pain. Completed NCT03047278 Phase 4 Gabapentin 300 mg;Cetirizine Hydrochloride 10 mg
10 A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
11 A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN). Completed NCT00156078 Phase 4 pregabalin
12 Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading Completed NCT02439879 Phase 4 Alpha lipoic acid
13 A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
14 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapyâ„¢ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
15 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
16 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
17 A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
18 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
19 A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride
20 A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
21 The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes Completed NCT00931879 Phase 4 omega-3-ethyl esters;Placebo
22 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4 Drug Placebo Administration
23 Comparative Evaluation of Standard Wearing Shoes With Rocker Sole Shoes in Diabetic Patients With Neuropathy Completed NCT02891928 Phase 4
24 An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
25 A Comparative Study Of Botulinum Toxin Type A Versus Conventional Oral Therapy As A Second Line Treatment Of Diabetic Neuropathy Completed NCT05296759 Phase 4 botulinum toxin A;Gabapentin;Duloxetine
26 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
27 A Multicenter Trial Evaluating the Efficacy of Cesametâ„¢ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesametâ„¢ (nabilone)
28 High-dose Vitamin D Supplementation Reduces Inflammation and Improves Microcirculation in Patients With Diabetic Peripheral Neuropathy Completed NCT04377399 Phase 4 Vitamin D
29 A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 120 mg QD
30 Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT00322621 Phase 4 Duloxetine
31 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
32 Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects Completed NCT02682901 Phase 4 Cycloset;Placebo
33 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
34 Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Completed NCT04193566 Phase 4 Forxiga
35 A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT02417935 Phase 4 Duloxetine;Pregabalin;Placebo
36 An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
37 Randomized Double Blind Placebo Controlled Multicenter Study of the Efficacy and Safety of Repeated Administrations of Botulinum Toxin Type A (Botox) in the Treatment of Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
38 A Randomised, Controlled, Cross-over Study With Inpatient and Outpatient Phases Completed NCT01352767 Phase 4
39 Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
40 Effect of High-Dose N-acetyl Cysteine (NAC) on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy (DPN) Recruiting NCT04766450 Phase 4 Acetyl cysteine
41 Efficacy and Safety of Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy: a Randomized, Parallel, Open-label, Multicenter, Phase IV Clinical Trial (OPTIMUM Trial) Recruiting NCT04846673 Phase 4 Pregabalin 150mg + Alpha-lipoic acid 480mg;Pregabalin 150mg;Alpha-Lipoic Acid 480mg
42 Precision Spinal Cord Stimulation for Painful Diabetic Neuropathy Terminated NCT00487981 Phase 4
43 Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy Terminated NCT00619983 Phase 4 donepezil;duloxetine;donepezil 2.5 mg and duloxetine 30mg;placebo;gabapentin
44 Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM) Terminated NCT04246619 Phase 4 Pregabalin;Duloxetine
45 A Double-Blind, Placebo-Controlled, Randomized, Parallel Assignment, U.S. Study of Ranolazine for the Treatment of Patients With Diabetic Peripheral Neuropathic Pain (DPNP) Terminated NCT02156336 Phase 4 Ranolazine;Placebo
46 Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin: a Randomized Controlled Flexible-dose Study in Patients With Neuropathic Pain Withdrawn NCT01116531 Phase 4 Tramadol;Duloxetine;Pregabalin
47 Diabetic Neuropathic Pain Topical Treatment- Comparative Study Unknown status NCT00661063 Phase 3 ketamine;vehicle gel;ketamine + clonidine;clonidine gel 1%
48 The Benefits of Astaxanthin as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient: Randomized Clinical Trial Unknown status NCT04689984 Phase 2, Phase 3 Standard therapy;Astaxanthin
49 The Benefits of Vitamin D 5000 IU as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient: Randomized Clinical Trial Unknown status NCT04689958 Phase 2, Phase 3 Standard therapy;Vitamin D 5,000IU Oral Tablet
50 The Benefits of Vitamin B Combination as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient: Randomized Clinical Trial Unknown status NCT04689971 Phase 2, Phase 3 Standard therapy;Vitamin B combination

Search NIH Clinical Center for Diabetic Neuropathy

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Becaplermin
CAPSACIAN PWDR
Capsaicin
CAPSAICIN PWDR
Capsicum extract
CAPSICUM OLEORESIN
Citalopram
Citalopram hydrobromide
COBALAMIN CONCENTRATE
Hydroxocobalamin
HYDROXOCOBALAMIN ACETATE
mecobalamin
Mexiletine
Mexiletine Hydrochloride
Pentoxifylline
Vitamin B 12

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diabetic Neuropathy cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Diabetic Neuropathy:
Hematopoietic stem cells for limb ischemia and diabetic neuropathy
Embryonic/Adult Cultured Cells Related to Diabetic Neuropathy:
Peripheral blood-derived hematopoietic stem cells (family)
Sources

Genetic Tests for Diabetic Neuropathy

About this section
Sources

Anatomical Context for Diabetic Neuropathy

About this section

Organs/tissues related to Diabetic Neuropathy:

MalaCards : Spinal Cord, Bone Marrow, Dorsal Root Ganglion, Skin, Brain, Bone, Eye
Sources

Publications for Diabetic Neuropathy

About this section

Articles related to Diabetic Neuropathy:

(show top 50) (show all 7663)
# Title Authors PMID Year
1
Therapeutic strategies for diabetic neuropathy. 53 62
20425233 2010
2
A current update on the use of alpha lipoic acid in the management of type 2 diabetes mellitus. 53 62
19601918 2009
3
Expression of neurotrophic factors in diabetic muscle--relation to neuropathy and muscle strength. 53 62
19696031 2009
4
Neuropathy is associated with depression independently of health-related quality of life in Japanese patients with diabetes. 53 62
19067994 2009
5
Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: an Indian perspective. 53 62
19893679 2008
6
Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. 53 62
18644069 2008
7
Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. 53 62
18447661 2008
8
Aldose reductase, still a compelling target for diabetic neuropathy. 53 62
18220710 2008
9
Epidemiology and management of type 1 diabetes mellitus at the ain shams university pediatric hospital. 53 62
18992206 2008
10
Pharmacologic intervention in axonal excitability: in vivo assessment of nodal persistent sodium currents in human neuropathies. 53 62
20021424 2008
11
sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. 53 62
18046662 2007
12
Pyridine nucleotide redox abnormalities in diabetes. 53 62
17508915 2007
13
Levels of three distinct p75 neurotrophin receptor forms found in human plasma are altered in type 2 diabetic patients. 53 62
17492429 2007
14
Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. 53 62
17521436 2007
15
Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. 53 62
17327338 2007
16
Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis. 53 62
17187935 2007
17
Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat. 53 62
17063327 2006
18
Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy. 53 62
17070440 2006
19
Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component. 53 62
18220622 2006
20
Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics. 53 62
16717216 2006
21
Induction of heat shock proteins may combat insulin resistance. 53 62
16309849 2006
22
Advanced Diabetic Neuropathy: A Point of no Return? 53 62
17487338 2006
23
Talin immunogold density increases in sciatic nerve of diabetic rats after nerve growth factor treatment. 53 62
16528132 2006
24
Are Type 2 diabetic patients offered adequate foot care? The role of physician and patient characteristics. 53 62
16260348 2005
25
Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus. 53 62
16268804 2005
26
The association of aldose reductase gene (AKR1B1) polymorphisms with diabetic neuropathy in adolescents. 53 62
16176189 2005
27
A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. 53 62
16112498 2005
28
Retinoic acid increases tissue and plasma contents of nerve growth factor and prevents neuropathy in diabetic mice. 53 62
15733075 2005
29
Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004? 53 62
15539002 2004
30
C-peptide: much more than a byproduct of insulin biosynthesis. 53 62
15367890 2004
31
Direct insulin signaling of neurons reverses diabetic neuropathy. 53 62
15220207 2004
32
Biochemical pharmacology of the vanilloid receptor TRPV1. An update. 53 62
15128291 2004
33
Aldose reductase structures: implications for mechanism and inhibition. 53 62
15095000 2004
34
Outcomes of decompression surgery for lumbar spinal stenosis in elderly diabetic patients. 53 62
14614597 2004
35
Neurotrophic factors and their receptors in human sensory neuropathies. 53 62
14699981 2004
36
Clinical potential of aldose reductase inhibitors in diabetic neuropathy. 53 62
16026107 2004
37
Nitrosative injury and antioxidant therapy in the management of diabetic neuropathy. 53 62
14989368 2004
38
New insights into the metabolic and molecular basis for diabetic neuropathy. 53 62
14625688 2003
39
Fidarestat. Sanwa Kagaku/NC Curex/Sankyo. 53 62
14649216 2003
40
Genetic analysis of aldose reductase in diabetic complications. 53 62
12871135 2003
41
Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. 53 62
12924487 2003
42
Enhanced activation of axonally transported stress-activated protein kinases in peripheral nerve in diabetic neuropathy is prevented by neurotrophin-3. 53 62
12805110 2003
43
Selective decrease in axonal nerve growth factor and insulin-like growth factor I immunoreactivity in axonopathies of unknown etiology. 53 62
12677448 2003
44
Acute painful neuropathy (insulin neuritis) in a boy following rapid glycemic control for type 1 diabetes mellitus. 53 62
12822825 2003
45
Insulin deficiency rather than hyperglycemia accounts for impaired neurotrophic responses and nerve fiber regeneration in type 1 diabetic neuropathy. 53 62
12638730 2003
46
A thematic approach to enhance clinical content in a cell and tissue biology course. 53 62
12431955 2002
47
Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? 53 62
12198818 2002
48
Continuous delivery of neurotrophin 3 by gene therapy has a neuroprotective effect in experimental models of diabetic and acrylamide neuropathies. 53 62
11779407 2001
49
Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. 53 62
11701599 2001
50
Diabetic neuropathy: pathogenetic background, current and future therapies. 53 62
19811034 2001
Sources

Variations for Diabetic Neuropathy

About this section
Sources

Expression for Diabetic Neuropathy

About this section
Search GEO for disease gene expression data for Diabetic Neuropathy.
Sources

Pathways for Diabetic Neuropathy

About this section

Pathways related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
MIF Mediated Glucocorticoid Regulation 64
Show member pathways
 13.44 VEGFA SOD2 NTRK1 NGFR NGF INS
2
CREB Pathway 64
Show member pathways
 13.15 TRPV4 TRPV1 TRPM8 NTRK1 NTF3 NGFR
3
p70S6K Signaling 64
Show member pathways
 12.87 NTRK1 NTF3 NGFR NGF INS ACE
4
PI3K-Akt signaling pathway 74
Show member pathways
 12.75 VEGFA NTRK1 NTF3 NGFR NGF INS
5
Signaling by Receptor Tyrosine Kinases 66
12.65 VEGFA NTRK1 NTF3 NGF INS
6
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.46 NTRK1 NTF3 NGFR NGF EPO
7
Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases 22
Show member pathways
 12.4 NTRK1 NTF3 NGFR NGF
8
Hepatocyte growth factor receptor signaling 74
Show member pathways
 12.26 TRPV1 NTRK1 NTF3 NGFR NGF
9
Malignant pleural mesothelioma 74
12.11 VEGFA NTRK1 NTF3 NGFR NGF INS
10
p75(NTR)-mediated signaling 61
Show member pathways
 11.49 NTRK1 NTF3 NGFR NGF
11
Neurogenesis regulation in the olfactory epithelium 74
11.43 NTRK1 NGFR NGF
12
SHP2 signaling 61
11.36 NGF NTF3 NTRK1 VEGFA
13
Neurotrophic factor-mediated Trk receptor signaling 61
Show member pathways
 11.28 NTRK1 NTF3 NGFR NGF
14
Pluripotent stem cell differentiation pathway 74
11.14 VEGFA INS EPO CNTF
15
TRP channels 66
11.08 TRPM8 TRPV1 TRPV4
16
Neural Stem Cells and Lineage-specific Markers 65
10.92 VEGFA NTF3 NGF GDNF CNTF
Sources

GO Terms for Diabetic Neuropathy

About this section

Cellular components related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.2 VEGFA SOD3 NTF3 NGFR NGF INS
2 extracellular space GO:0005615 10 ACE AKR1B1 CNTF EPO GDNF INS
3 plasma membrane GO:0005886 9.7 TRPV4 TRPV1 TRPM8 NTRK1 NGFR MPZ
4 plasma membrane GO:0005887 9.7 TRPV4 TRPV1 TRPM8 NTRK1 NGFR MPZ

Biological processes related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 10.36 CNTF EPO GDNF INS NTF3 VEGFA
2 nervous system development GO:0007399 10.23 VEGFA NTRK1 NTF3 NGFR GDNF CNTF
3 negative regulation of apoptotic process GO:0043066 10.21 VEGFA SOD2 NTRK1 MPZ GDNF EPO
4 aging GO:0007568 10.19 SOD2 NTRK1 EPO ACE
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.16 VEGFA TRPV4 NTRK1 EPO AGER
6 regulation of synaptic plasticity GO:0048167 10.08 INS AGER ACE
7 response to axon injury GO:0048678 10.02 SOD2 NTRK1 EPO
8 cellular response to amyloid-beta GO:1904646 9.97 AGER NGFR NTRK1
9 response to electrical stimulus GO:0051602 9.97 SOD2 NTRK1 EPO
10 positive regulation of Ras protein signal transduction GO:0046579 9.95 EPO NGF NTRK1
11 response to nutrient levels GO:0031667 9.95 ACE NTRK1 SOD2 SORD
12 sensory perception of pain GO:0019233 9.9 TRPV1 NTRK1 ACE
13 detection of temperature stimulus GO:0016048 9.86 TRPM8 NGFR
14 induction of positive chemotaxis GO:0050930 9.85 VEGFA NTF3 AGER
15 thermoception GO:0050955 9.84 TRPV1 TRPM8
16 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.83 VEGFA ACE
17 nerve development GO:0021675 9.8 NTF3 NGFR NGF
18 fructose biosynthetic process GO:0046370 9.76 SORD AKR1B1
19 peripheral nervous system development GO:0007422 9.76 PMP22 NTF3 NGF GDNF
20 nerve growth factor signaling pathway GO:0038180 9.73 NGF NTF3 NTRK1
21 response to hypoxia GO:0001666 9.73 VEGFA SOD3 SOD2 EPO AGER ACE
22 negative regulation of neuron apoptotic process GO:0043524 9.4 SOD2 NTRK1 NTF3 NGF GDNF CNTF

Molecular functions related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 monoatomic cation channel activity GO:0005261 9.72 TRPV4 TRPV1 TRPM8
2 nerve growth factor binding GO:0048406 9.67 NTRK1 NGFR
3 nerve growth factor receptor binding GO:0005163 9.56 NTF3 NGF
4 superoxide dismutase activity GO:0004784 9.46 SOD3 SOD2
5 growth factor activity GO:0008083 9.32 VEGFA NTF3 NGF GDNF CNTF
6 neurotrophin binding GO:0043121 9.26 NTRK1 NGFR
Sources

Sources for Diabetic Neuropathy

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....